KYMR - Kymera Therapeutics, Inc.
About Kymera Therapeutics, Inc. (https://www.kymeratx.com)
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | 1979 | $1,226,750 USD |
| Jared A. Gollob | Chief Medical Officer | 1965 | $806,344 USD |
| Bruce N. Jacobs | Chief Financial Officer | – | $795,250 USD |
| Jeremy G. Chadwick | Chief Operating Officer | 1963 | $719,400 USD |
| Noah Goodman | Chief Business Officer | 1987 | $597,289 USD |
| Brian R. Adams | Chief Legal Officer & Corporate Secretary | 1974 | $540,095 USD |
| Bruce L. Booth DPHIL | Co-Founder & Independent Chairman | 1974 | $70,000 USD |
| Juliet Williams | Head of Research | – | – |
| Justine E. Koenigsberg | Vice President of Investor Relations | – | – |
| Karen Weisbach | Head of People & Culture | – | – |
| Neil Graham MBBS | Chief Development Officer | 1959 | – |